DKSH entered a strategic agreement with Kyowa Kirin, a Japanese global specialty pharmaceutical company, to deliver comprehensive specialty medicine services in South Korea, Taiwan, Singapore, Thailand, Malaysia, and Hong Kong & Macau SAR.
This alliance improves patient care and accessibility in the region with DKSH’s knowledge, distribution networks, and commercial capabilities.
In keeping with Kyowa Kirin’s announced plans to transform its business in Asia-Pacific, DKSH Business Unit Healthcare, a Strategic Healthcare Solutions Partner and leading provider of Market Expansion Services for pharmaceutical, over-the-counter (OTC), consumer health, and medical device companies, enters into a partnership with Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto), a global specialty pharmaceutical company based in Japan.
Read also- China-Based Lenovo has Partnered with Databricks
Bijay Singh, Global Head Business Unit Healthcare, Member of the Executive Committee, DKSH, added: “We are thrilled to embark on this brand new partnership with Kyowa Kirin, especially as they chose DKSH as a regional partner across 6 markets. This collaboration reflects DKSH’s commitment to driving growth for our clients while at the same time pursuing our mission of providing better healthcare to all patients in our markets. By combining our expertise and resources with Kyowa Kirin’s excellent brands, we are confident we can provide a more cost-effective yet high quality commercial access solution that provides outstanding patient outcomes and customer service.”
Acknowledged for providing a comprehensive array of integrated solutions to foster long-term growth for client partners, Kyowa Kirin has selected DKSH as a strategic partner to execute a comprehensive agency alliance business model that prioritizes patient access to end-to-end healthcare solutions. With DKSH’s extensive nephrology knowledge, strong commercial capabilities, and solid distribution networks, this partnership furthers a major advancement in patient care and accessibility in the area.
Read also- China-Based Deep Blue Aerospace has Secured $139.7 Million in Series B2 Round Funding
“We are very confident about this new journey with DKSH”, stated Abdul Mullick, Ph.D., Chief International Business Officer (CIBO), Kyowa Kirin. “Given DKSH’s proven healthcare expertise and commercial strength across Southeast Asia and North Asia, we are convinced we have chosen the right business partner to continue serving our patients, taking care of our employees and making people smile.”
About Kyowa Kirin
Kyowa Kirin seeks life-changing medications. For over 70 years, Japan-based Global Specialty Pharmaceutical Company has invested in drug discovery and biotechnology innovation. They are currently engineering the next generation of antibodies and cell and gene therapies to help patients with severe or rare diseases.
About Dksh
DKSH mission is to improve lives. DKSH’s Healthcare, Consumer Goods, Performance Materials, and Technology Business Units have helped Asian and global firms grow for almost 160 years. DKSH is a leading Market Expansion Services provider, including sourcing, market analytics, marketing and sales, eCommerce, distribution, logistics, and after-sales services.
